Voyager Therapeutics Future Growth
Future criteria checks 0/6
Voyager Therapeutics's revenue and earnings are forecast to decline at 11.7% and 28.8% per annum respectively. EPS is expected to decline by 19.9% per annum. Return on equity is forecast to be -24.5% in 3 years.
Key information
-28.8%
Earnings growth rate
-19.9%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | -11.7% |
| Future return on equity | -24.5% |
| Analyst coverage | Good |
| Last updated | 22 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 69 | -107 | -87 | -80 | 7 |
| 12/31/2025 | 60 | -111 | -120 | -116 | 10 |
| 12/31/2024 | 89 | -55 | -32 | -28 | 9 |
| 9/30/2024 | 164 | 26 | -29 | -25 | N/A |
| 6/30/2024 | 144 | 9 | -22 | -18 | N/A |
| 3/31/2024 | 119 | -3 | 8 | 13 | N/A |
| 12/31/2023 | 250 | 132 | 75 | 78 | N/A |
| 9/30/2023 | 158 | 52 | 86 | 89 | N/A |
| 6/30/2023 | 195 | 96 | 91 | 94 | N/A |
| 3/31/2023 | 191 | 99 | 74 | 77 | N/A |
| 12/31/2022 | 41 | -46 | -15 | -13 | N/A |
| 9/30/2022 | 71 | -17 | 9 | 11 | N/A |
| 6/30/2022 | 31 | -60 | 4 | 6 | N/A |
| 3/31/2022 | 32 | -71 | 1 | 2 | N/A |
| 12/31/2021 | 37 | -71 | -55 | -54 | N/A |
| 9/30/2021 | 16 | -93 | -92 | -87 | N/A |
| 6/30/2021 | 132 | 18 | -100 | -91 | N/A |
| 3/31/2021 | 160 | 39 | -100 | -89 | N/A |
| 12/31/2020 | 171 | 37 | -109 | -97 | N/A |
| 9/30/2020 | 197 | 40 | -110 | -98 | N/A |
| 6/30/2020 | 100 | -61 | -103 | -95 | N/A |
| 3/31/2020 | 117 | -41 | -113 | -105 | N/A |
| 12/31/2019 | 104 | -44 | 41 | 49 | N/A |
| 9/30/2019 | 74 | -54 | 43 | 48 | N/A |
| 6/30/2019 | 55 | -59 | 47 | 52 | N/A |
| 3/31/2019 | 12 | -96 | 57 | 61 | N/A |
| 12/31/2018 | 8 | -88 | -20 | -16 | N/A |
| 9/30/2018 | 12 | -78 | -10 | -6 | N/A |
| 6/30/2018 | 11 | -81 | N/A | -5 | N/A |
| 3/31/2018 | 10 | -74 | N/A | 2 | N/A |
| 12/31/2017 | 10 | -71 | N/A | -61 | N/A |
| 9/30/2017 | 6 | -74 | N/A | -60 | N/A |
| 6/30/2017 | 8 | -59 | N/A | -54 | N/A |
| 3/31/2017 | 11 | -50 | N/A | -47 | N/A |
| 12/31/2016 | 14 | -40 | N/A | -42 | N/A |
| 9/30/2016 | 17 | -34 | N/A | -39 | N/A |
| 6/30/2016 | 18 | -32 | N/A | -36 | N/A |
| 3/31/2016 | 20 | -30 | N/A | -33 | N/A |
| 12/31/2015 | 17 | -38 | N/A | 41 | N/A |
| 9/30/2015 | 12 | -35 | N/A | 46 | N/A |
| 6/30/2015 | 7 | -32 | N/A | 50 | N/A |
| 3/31/2015 | 3 | -30 | N/A | 55 | N/A |
| 12/31/2014 | N/A | -18 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VT6's earnings are forecast to decline over the next 3 years (-28.8% per year).
Earnings vs Market: VT6's earnings are forecast to decline over the next 3 years (-28.8% per year).
High Growth Earnings: VT6's earnings are forecast to decline over the next 3 years.
Revenue vs Market: VT6's revenue is expected to decline over the next 3 years (-11.7% per year).
High Growth Revenue: VT6's revenue is forecast to decline over the next 3 years (-11.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VT6 is forecast to be unprofitable in 3 years.